New pill aims to calm gut side effects from cancer treatment
NCT ID NCT07196410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called KAN-004 in 21 adults who have diarrhea or colon inflammation from cancer immunotherapy. The main goal is to see if the drug is safe and tolerable. Participants must have a solid tumor and be at least 18 years old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier de l'Universite de Montreal
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold key to treating severe colitis
- New antibody cocktail aims to tame ulcerative colitis for good
- New hope for immunotherapy side effects: blood filtering may replace steroids
- Could a simple food supplement tame ulcerative colitis?
- Real-World study to see how long IBD patients stick with guselkumab
- New Light-Based scanner aims to spot inflammation without needles